Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis

What Was Tested

This randomized controlled trial paper looks at Cyanocobalamin (Vitamin B12).

This study had an open-label nature and did not examine long-term effects of homocysteine-normalizing therapy (no clinical end points).

Who Took Part

According to the abstract, 40 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

40 patients were randomly assigned to 1 of 2 groups.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Cyanocobalamin (Vitamin B12) study: the patients and staff both knew the treatment.

Blood samples were collected under fasting conditions during the prehemodialysis procedure.

What Was Measured

This study had an open-label nature and did not examine long-term effects of homocysteine-normalizing therapy (no clinical end points).

The subject headings attached to it are Arginine, Cardiovascular Diseases, Folic Acid, Homocysteine, Hyperhomocysteinemia, Kidney Failure, Chronic and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized and open-label study of Cyanocobalamin (Vitamin B12) in 40 patients.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.